Public Consultations are held regularly as a form of soliciting public input on the draft documents produced by EUnetHTA within the framework of implementing the EUnetHTA Joint Action 2 grant agreement and 3-year EUnetHTA Joint Action 2 Work Plan. Announcements of the public consultations are made in the News section of this website.

Properly submitted contributions will be made public on the EUnetHTA public website within a month after the closing date of the public consultation (unless the author has explicitly opposed publication of their contribution or the contributions do not address the draft documents put forward for public consultation or contain complaints against institutions, personal accusations, irrelevant or offensive statements or material). The name of the author, his affiliation, and date of the submission’s receipt will be disclosed when the contribution is made public.

More detailed instructions are provided on the news dedicated for each specific public consultation.

The EC-EUnetHTA Forum "European cooperation on HTA: what's next?" co-organised by the European Commission and the EUnetHTA Joint Action 3 was the first meeting between all 79 EUnetHTA partner organisations and the broader HTA stakeholder community.
We are pleased to announce that as of today, 11March 2016, the draft methodological reflection paper “Personalised medicine and co-dependent technologies, with a special focus on study design issues”, produced within WP7 - Subgroup 3, has entered the public consultation phase. This consultation will take place between 11 March and 15 April 2016.
We are happy to announce that the third Core HTA produced within the EUnetHTA Joint Action 2 Work Package 4 is available for public feedback. The topic assessed is “Structured telephone support (STS) for adult patients with chronic heart failure”
We are pleased to announce that as of today, 21 October, 2015, the methodological guideline “Endpoints used in Relative Effectiveness Assessment - Safety”, originally published in March 2013 and now adapted within WP7 - Subgroup 3, has entered the public consultation phase.
We are pleased to announce that as of today, 15 October, the Second Draft Report focusing on the production of a Rapid Relative Effectiveness Assessment of new pharmaceuticals for the treatment of chronic hepatitis C by Work Package 5, Strand A has entered the public consultation phase.